Notification

🚨 Trading Holiday 🚨

The NSE and BSE will remain closed for trading and settlement on Monday, April 14, 2025, on account of Dr. B. R. Ambedkar Jayanti.

Open a Free Demat Account

Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.

Trade Now, Pay Later with up to 4x

Never miss a good trading opportunity due to low funds with our MTF feature.

Track Market Movers Instantly

Stay updated with real-time data. Get insights at your fingertips.

NSE BSE

Trade Nowopens in a new tab

Automobile Products Of India L Share Price

₹ 4.5 0.00 (0.00%)

Oct 12 2000 12:00 AM Miscellaneous NSE: AUTOPRD

Automobile Products Of India L Share Price Update

As of the latest trading session, Automobile Products Of India L share price is currently at 4.5, which is up by 0.00 from its previous closing. Today, the stock has fluctuated between 4.50 and 4.50. Over the past year, Automobile Products Of India L has achieved a return of 0.0 %. In the last month alone, the return has been 0.0 %. Read More...

Automobile Products Of India L Performance

Day Range

Low4.50 High4.50

4.50

52 Week Range

Low .00 High 4.50

4.50

Automobile Products Of India L Share Price

505032

AUTOPRD

Compare to down-arrow

View

Display

Studies

No Data Available

Open Price

4.50 Prev. Close

4.50 Volume (Shares)

100.00 Total traded value

.00

Upper Circuit

4.72 Lower Circuit

4.28

Note: The current prices & values are delayed, Loginopens in a new tab to your account for live updates.

Automobile Products Of India L Fundamentals

(Standalone)

Market Cap (Cr)	0.0
PE Ratio (TTM)	0.0
Book Value / Share	0.0
Beta	0.0

ROE	0.0%
EPS (TTM)	0.0
Dividend Yield	0.0%
Net Profit Qtr (Cr)	0.0

Automobile Products Of India L Financials

Key Results
Key Ratios
Balance sheet
Cash Flow
Competition

Revenue

Net income

Particulars	DEC 2024 (Values in Cr)
Revenue	0.04
Operating Expense	0.61
Net Profit	-0.40
Net Profit Margin (%)	-1000.00
Earnings Per Share (EPS)	-0.82
EBITDA	0.00
Effective Tax Rate (%)	0.00

Particulars	SEP 2024 (Values in Cr)
Revenue	0.04
Operating Expense	0.64
Net Profit	-0.44
Net Profit Margin (%)	-1100.00
Earnings Per Share (EPS)	-0.90
EBITDA	-0.03
Effective Tax Rate (%)	0.00

Particulars	JUN 2024 (Values in Cr)
Revenue	0.04
Operating Expense	0.60
Net Profit	-0.39
Net Profit Margin (%)	-975.00
Earnings Per Share (EPS)	-0.80
EBITDA	0.00
Effective Tax Rate (%)	0.00

Particulars	MAR 2024 (Values in Cr)
Revenue	0.04
Operating Expense	0.86
Net Profit	-0.66
Net Profit Margin (%)	-1650.00
Earnings Per Share (EPS)	-1.36
EBITDA	-0.45
Effective Tax Rate (%)	1.51

Particulars	DEC 2023 (Values in Cr)
Revenue	0.04
Operating Expense	0.42
Net Profit	-0.22
Net Profit Margin (%)	-550.00
Earnings Per Share (EPS)	-0.46
EBITDA	-0.01
Effective Tax Rate (%)	0.00

Particulars	MAR 2024 (Values in Cr)
Revenue	0.17
Operating Expense	2.03
Net Profit	-1.24
Net Profit Margin (%)	-729.41
Earnings Per Share (EPS)	-2.57
EBITDA	-0.42
Effective Tax Rate (%)	0.80

Particulars	MAR 2023 (Values in Cr)
Revenue	0.17
Operating Expense	1.45
Net Profit	-0.84
Net Profit Margin (%)	-494.11
Earnings Per Share (EPS)	-1.75
EBITDA	-0.16
Effective Tax Rate (%)	1.17

Particulars	MAR 2022 (Values in Cr)
Revenue	0.17
Operating Expense	1.49
Net Profit	-0.84
Net Profit Margin (%)	-494.11
Earnings Per Share (EPS)	-1.74
EBITDA	0.02
Effective Tax Rate (%)	0.00

Particulars	MAR 2021 (Values in Cr)
Revenue	0.17
Operating Expense	1.68
Net Profit	-4.94
Net Profit Margin (%)	-2905.88
Earnings Per Share (EPS)	-10.25
EBITDA	-0.01
Effective Tax Rate (%)	-329.56

Particulars	MAR 2020 (Values in Cr)
Revenue	0.18
Operating Expense	1.48
Net Profit	10.96
Net Profit Margin (%)	6088.88
Earnings Per Share (EPS)	22.76
EBITDA	16.08
Effective Tax Rate (%)	27.68

Particulars	MAR 2024 (Values in Cr)
Book Value / Share	-24.91
ROE %	0.00
ROCE %	0.00
Total Debt to Total Equity	0.00
EBITDA Margin	-247.06

Particulars	MAR 2023 (Values in Cr)
Book Value / Share	-22.32
ROE %	0.00
ROCE %	0.00
Total Debt to Total Equity	0.00
EBITDA Margin	-100.00

Particulars	MAR 2022 (Values in Cr)
Book Value / Share	-20.54
ROE %	0.00
ROCE %	0.00
Total Debt to Total Equity	0.00
EBITDA Margin	5.88

Particulars	MAR 2021 (Values in Cr)
Book Value / Share	-18.77
ROE %	0.00
ROCE %	0.00
Total Debt to Total Equity	0.00
EBITDA Margin	-17.65

Particulars	MAR 2020 (Values in Cr)
Book Value / Share	-8.50
ROE %	14.42
ROCE %	-1.63
Total Debt to Total Equity	0.00
EBITDA Margin	-44.44

Particulars	MAR 2024 (Values in Cr)
Cash & Short Term Investments	9.48
Total Assets	10.27
Total Liabilities	10.27
Total Equity	-12.00
Share Outstanding	4817656
Price to Book Ratio	0.00
Return on Assets (%)	-12.03
Return on Capital (%)	-183.14

Particulars	MAR 2023 (Values in Cr)
Cash & Short Term Investments	8.93
Total Assets	9.05
Total Liabilities	9.05
Total Equity	-10.75
Share Outstanding	4817656
Price to Book Ratio	0.00
Return on Assets (%)	-9.31
Return on Capital (%)	-221.76

Particulars	MAR 2022 (Values in Cr)
Cash & Short Term Investments	8.53
Total Assets	8.67
Total Liabilities	8.67
Total Equity	-9.89
Share Outstanding	4817656
Price to Book Ratio	0.00
Return on Assets (%)	-9.66
Return on Capital (%)	-11329.73

Particulars	MAR 2021 (Values in Cr)
Cash & Short Term Investments	8.22
Total Assets	10.30
Total Liabilities	10.30
Total Equity	-9.04
Share Outstanding	4817656
Price to Book Ratio	0.00
Return on Assets (%)	-47.91
Return on Capital (%)	-301.79

Particulars	MAR 2020 (Values in Cr)
Cash & Short Term Investments	0.05
Total Assets	15.28
Total Liabilities	15.28
Total Equity	-4.09
Share Outstanding	4817656
Price to Book Ratio	0.00
Return on Assets (%)	71.71
Return on Capital (%)	213.06

Particulars	MAR 2024 (Values in Cr)
Net Income	-1.24
Cash from Operations	-1.34
Cash from Investing	0.06
Cash from Financing	0.72
Net change in Cash	-0.60
Free Cash Flow	-1.34

Particulars	MAR 2023 (Values in Cr)
Net Income	-0.85
Cash from Operations	-0.58
Cash from Investing	0.63
Cash from Financing	0.55
Net change in Cash	0.59
Free Cash Flow	-0.58

Particulars	MAR 2022 (Values in Cr)
Net Income	-0.84
Cash from Operations	0.13
Cash from Investing	-0.47
Cash from Financing	-1.62
Net change in Cash	0.03
Free Cash Flow	0.13

Particulars	MAR 2021 (Values in Cr)
Net Income	-1.15
Cash from Operations	0.02
Cash from Investing	-0.35
Cash from Financing	0.32
Net change in Cash	-0.04
Free Cash Flow	0.02

Particulars	MAR 2020 (Values in Cr)
Net Income	15.16
Cash from Operations	-14.44
Cash from Investing	16.57
Cash from Financing	-0.15
Net change in Cash	0.01
Free Cash Flow	-14.44

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
KESORAM INDUSTRIES LTD	3.77	0.00	-3.68	117.14	3.66 / 11.79
MODI RUBBER LTD	104.70	11.67	0.47	262.17	86.05 / 156.75
THOMAS COOK (INDIA) LTD	131.40	24.89	4.02	6187.54	118.10 / 264.00
RAIN INDUSTRIES LIMITED	137.80	0.00	0.69	4634.90	117.30 / 196.95
GANESH BENZOPLAST LIMITED	119.70	13.14	1.61	861.71	100.70 / 182.95

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
FGP LTD.	8.98	47.26	2.87	10.68	5.85 / 14.18
KESORAM INDUSTRIES LTD	3.77	0.00	0.51	117.14	3.66 / 11.79
MPIL CORPORATION LTD.	620.00	0.00	2.36	35.34	506.00 / 1033.00
MODI RUBBER LTD	104.70	24.29	0.97	262.17	86.05 / 156.75

Technicals

EMA & SMA
Resistance and Support
Price Change Analysis

Bullish Moving Averages -

Bearish Moving Averages -

5 Days 0.00
26 Days 0.00
10 Days 0.00
50 Days 0.00
12 Days 0.00
100 Days 0.00
20 Days 0.00
200 Days 0.00

0.0
PIVOT

First Resistance	0.0
Second Resistance	0.0
Third Resistance	0.0

First Support	0.0
Second Support	0.0
Third Support	0.0

RSI	0.0
MACD	0.0
Commodity Channel Index (CCI)	0.0

ADX	0.0
Williams % R	0.0

Automobile Products Of India L Future

Future: Price

25 May

0 100 200 300 400 500 600

Discount/Premium

25 May

0 1 2 3 4 5 6 7

Active Calls

25 May

0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul

0 500 1000 1500 2000 2500

Stock Holding

View Live Stock Screeners

Holding

Public

14.8 Promoter Holdings

84.71 FII

0.0 DII

0.47 Promoter Shares(Pledge Percentage)

0.0

Name	Category	Shares	Shares%
Kiyana Real Estate Private Limited	Shareholding of Promoter and Promoter Group	4081122.0	84.71
Mrigashish Investment And Trading Company Private Limited	Public Shareholding	53600.0	1.11
K C Holdings Private Limited	Public Shareholding	53200.0	1.1

Automobile Products Of India L

Ex-Date	Dividend Amt.	Dividend Type	Record Date	Instrument Type

Learn More About Stocks

Dr Reddy’s Denies Workforce Reduction Claims Amid Cost-Cut Rumours

Dr Reddy’s Laboratories rejects claims of reducing workforce costs by 25%, asserting no such plans or internal directives.

15 Apr, 2025 | 3 Min. read

Glenmark, Sun Pharma, Zydus Recall Drugs in US over Compliance Issues

Glenmark, Sun Pharma, and Zydus recall multiple drug batches in the US following manufacturing deviations and contamination concerns as per USFDA enforcement reports.

15 Apr, 2025 | 3 Min. read

HAL Denies Selecting PwC for R&D Benchmarking Amid Ongoing Bids

HAL clarifies no consultancy firm has been finalised for R&D benchmarking amid social media buzz about PwC. Selection process still ongoing via GeM portal.

15 Apr, 2025 | 3 Min. read

Aurobindo Pharma Gets USFDA Nod for Generic Xarelto 2.5mg Tablets

Aurobindo Pharma receives USFDA approval to launch generic Xarelto 2.5mg in Q1 FY26, targeting $447 million US market; higher strengths also gain tentative nod.

15 Apr, 2025 | 3 Min. read

IndiGo Becomes World’s Most Valuable Airline With $23.4 Billion Market Cap

IndiGo surpasses global peers to become the most valuable airline by market cap at $23.4 billion, pushing InterGlobe Aviation share price to record highs in 2025.

11 Apr, 2025 | 3 Min. read

SRF Ltd. Commissions New Agrochemical Unit in Dahej Worth Rs.239 Crore

SRF Ltd. starts new agrochemical facility in Dahej, Gujarat with Rs.239 crore investment. Phase 1 operational, full commissioning set for April 2025.

11 Apr, 2025 | 3 Min. read

Tata Motors’ JLR India Achieves Record Sales in FY25 at 6,183 Units

JLR India posts record-breaking FY25 retail sales of 6,183 units, up 40%. Defender leads growth, boosting Tata Motors share price sentiment.

11 Apr, 2025 | 4 Min. read

Biocon Gets USFDA Approval for Jobevne, Expands Oncology Portfolio

Biocon Biologics receives USFDA nod for cancer drug Jobevne, a bevacizumab biosimilar. Oncology portfolio in US grows, boosting Biocon Ltd. share price outlook.

11 Apr, 2025 | 3 Min. read